Definition and Pathophysiology of COPD
Chronic obstructive pulmonary disease affects more than 10% of the U.S. adult population (1, 2) . It is the fourth leading cause of death in the United States, accounting for over 100,000 deaths per year, and it is the second leading diagnosis for Social Security disability payment recipients (3) . COPD can be defined as chronic and mostly irreversible airflow limitation; conditions such as obstructing lesions of the central airways and bronchiectasis or cystic fibrosis are specifically excluded (4) . Chronic bronchitis, defined as chronic mucous hypersecretion leading to productive cough (4) , often coexists with chronic airflow obstruction and is generally considered part of the spectrum of COPD. Most of the morbidity and mortality caused by COPD, however, results from the chronic airflow obstruction and associated gas exchange and hemodynamic abnormalities rather than from the mucous hypersecretion (5, 6) . The primarily irreversible airflow limitation of COPD distinguishes it from asthma, which is characterized, at least in its early stages, by variable and largely reversible airflow limitation.
The defining physiologic characteristic of COPD is airflow obstruction on spirometry, i.e., a reduction in both FEV1 (the forced expiratory volume in 1 sec) and the FEV1/FVC (forced vital capacity) ratio. The airflow obstruction develops gradually and progressively over many years (7) . The eventual development of disabling COPD may result both from processes affecting lung growth and development in early life and from processes affecting longitudinal pulmonary function decline in adulthood (8, 9) . As the chronic airflow obstruction of COPD progresses, it may be accompanied by hyperinflation of the chest (physiologically measured as an increased total lung capacity) due to both gas trapping (physiologically measured as an increased residual volume) and loss of elastic recoil. These changes may eventually put the muscles of respiration at a mechanical disadvantage, with the resultant respiratory muscle dysfunction further worsening dyspnea, the cardinal symptom of COPD, and compromising functional status. Progressive worsening of ventilatory function ultimately leads to impaired gas exchange, with resultant hypoxemia and hypercapnia.
The histopathologic changes underlying the chronic airflow obstruction of COPD include both pulmonary emphysema and inflammatory disease of the small airways (10) . Emphysema is defined as abnormal enlargement of the alveolar airspaces caused by the destruction of the alveolar walls. This parenchymal destruction results in the reduction in alveolar attachments tethering open the bronchioles and the obliteration of functional alveolar-capillary units for gas exchange. In addition to emphysema, lung tissue from patients with COPD shows inflammation of the small airways (i.e., the bronchi with a diameter less than 2 mm and the bronchioles), with increased numbers of macrophages and neutrophils, goblet cell metaplasia, mucus plugging, and fibrosis. The loss of radial traction on the peripheral airways, due to the destruction of alveolar attachments, and the thickened bronchial walls, due to bronchiolitis, result in reduction in the radius of the airways and a consequent increase in airways resistance. There has been controversy about the relative contributions of parenchymal and airways disease to the airflow obstruction of COPD (11, 12) , although these two abnormalities are not independent inasmuch as the degree of small airways disease has been associated with the loss of alveolar attachment (13, 14) .
Although it seems clear that emphysema is often the major histopathologic abnormality for patients with severe COPD, small airways disease probably makes an important contribution and may be the major pathologic abnormality in some patients. The cellular and molecular mechanisms involved in the development of the airflow obstruction of COPD are not fully understood, and substantial heterogeneity in the pathogenesis of COPD likely exists. A model for understanding the development of this disease has emerged, however, from investigations of the major environmental risk factor for COPD (tobacco smoking) and of the most clearly understood genetic risk factor (API deficiency). In this model of COPD pathogenesis, the maintenance of healthy lung structure and function depends on the ability of homeostatic mechanisms to protect the airways and lung parenchyma from both environmental insults and the inflammatory responses to these insults (10 (16) . In cross-sectional surveys, smoking history is strongly associated with chronic respiratory symptoms, diagnosed chronic bronchitis and emphysema, and obstructive pulmonary function abnormalities (9) . Cohort studies have revealed that adult smokers experience faster longitudinal pulmonary function decline than nonsmokers (7, 17) and that this accelerated decline returns to the normal rate of aging-related decline following smoking cessation (9, 18) , even if the cessation is intermittent (19 This reduction of maximally attained function is hypothesized to predispose to impairment of pulmonary function in later life (51) .
Occupational exposure to biologic dusts has been established as a risk factor for COPD (52) . Grain dust exposure has been linked to chronic airflow obstruction in both cross-sectional (53-59) and longitudinal (60, 61) studies, an association that appears to be independent of the effects of tobacco smoking. The chronic airflow obstruction caused by grain dust exposure does not appear to be associated with either airway hyperreactivity or allergy to grain constituents (62) (63) (64) . Cotton dust exposure in the workplace has been reported to be associated with accelerated longitudinal lung function decline (65) , but not all studies confirm these findings (66) . Although acute byssinosis of cotton dust appears to be caused by the stimulation of endotoxin-mediated inflammatory mechanisms, it is not clear that endotoxin is responsible for the chronic airflow obstruction caused by long-term cotton dust exposure. The longest cohort study of cotton workers demonstrated an excess longitudinal decline of FEVI, compared to silk workers, most pronounced in the early years of exposure; loss of pulmonary function was independent of estimated exposure to inhaled endotoxin (65) . Other workplace biologic dusts implicated in the development of chronic airflow obstruction include cork (67), wood (68), sugar (69) , and paper dusts (70) .
Exposure to certain inorganic dusts in mining and other occupations has also been shown to be a risk factor for the development of chronic airflow obstruction independent of smoking and pneumoconiosis (71) (72) (73) . A meta-analysis (74) of studies of coal and gold miners demonstrated that airflow obstruction was common, more so in gold miners than coal miners. Silica has been implicated in the development of airflow obstruction (75) and the difference between gold miners and coal miners may be the result of higher silica exposure in the former group. Occupational chalk dust (69) and talc (76) exposure have also been reported to be associated with chronic airflow obstruction.
Although the mechanisms by which biologic and inorganic dusts lead to chronic airflow obstruction are not fully understood, many of the same mechanisms underlying the development of airflow obstruction from tobacco exposure may be involved. Particle deposition in the small airways may induce inflammatory responses, which lead to chronic airway changes as well as the development of centrilobular emphysema, as described above in relation to tobacco smoke. Dust-exposed groups have been noted to have goblet cell metaplasia and fibrosis of the membranous bronchioles beyond that seen in smokers (77). These changes were not seen in other portions of the bronchial tree.
Occupational exposure to chemical fumes and gases has also been linked to chronic airflow obstruction. Metal fumes, a product of metal working in a variety of industries, are associated with impairment of lung function. Welders and those exposed to metal fumes have been noted to have a lower FEV, (78) (79) (80) (81) (82) , and the duration of exposure is significantly related to the reduction of lung function (82). Indirect measures of metal buildup in the lungs correlate with the severity of lung function impairment (78).
Chlorine in various forms is used in many industries and frequently appears with other irritant gases. Pulp and paper mill workers, frequently exposed to chlorine and SO2 gases, have been reported to have a high prevalence of chronic airflow obstruction (70, 79, 83, 84 ).
The degree of airflow limitation is directly related to the degree of exposure, and there is at least an additive effect of smoking (84,85). Chlorine bleach, which frequently induces respiratory symptoms, has also been associated with a decline in lung function (70) , even with minimal history of tobacco use (84).
Chronic airflow obstruction has also been reported in association with long-term exposure to H2S (86), styrene and methyl methacrylate (87), and polyvinyl chloride (88). Fiberglass and modern insulation materials have inconsistent impact on airflow (80,89). For these various gases and fumes encountered in the workplace, the molecular and cellular mechanisms leading to chronic airflow obstruction remain uncertain, although direct chemical injury to the airway epithelium may be the initial event in the pathogenesis of airflow obstruction.
Outdoor air pollution is a hypothesized but unproven risk factor for the development of COPD (90 Studies of air pollution and lung function in children revealed lower levels of lung function (108) in children living in communities with higher levels of NO2, 03-, and particulate matter. The relation between lung function and SO2 in children is less clear (108) . Living in close proximity to a major point source of industrial emissions has been reported to be a risk factor for pulmonary functional impairment among children (109) .
Cohort studies suggest that the rate of longitudinal lung function decline in adults is related to ambient air pollution levels (105) . These studies, however, must be interpreted with caution because of potential imprecision in estimating pollution exposure as well as possible confounding factors. The quantitative impact of particular pollutants on pulmonary function is not fully understood, but dose-response relationships have been demonstrated in several studies (103, 110) , further suggesting an impact of air pollution on long-term lung function.
The combustion of heating and cooking fuels in indoor environments leads to the pollution of indoor air with respirable particles, nitrogen dioxide, and other pollutants. Although the contribution of these indoor pollutants to the risk of developing COPD is difficult to quantitate, several studies suggest a relation between indoor fuel combustion practices and COPD risk (111) (112) (113) (114) (115) . Exposure to indoor air pollution caused by fuel combustion is greater in poorer nations, and the potential health impact may vary accordingly.
The environment is not always inhospitable; some factors may help preserve pulmonary function and prevent COPD. The role of diet in the pathogenesis of lung disease is not clear, but as our understanding of the pathogenesis of COPD evolves, the potential role of diet increases. Antioxidant vitamins (including C and E) may provide a protective benefit, but the evidence remains controversial (116, 117) . Vitamin E treatment of children of smokers reduced the susceptibility to red blood cell peroxidation in vitro (118) . Certain (147) .
Emphysema, when present in severe API deficiency (Pi-Z), includes the lung bases in the overwhelming majority of cases (142) and has been suggested as a distinctive feature of this disorder.
Fewer (143) . These studies, however, are not without limitations and it has been proposed that Pi-MZ patients self-select away from exposures that would result in impaired pulmonary physiology (156) . Other studies have revealed subtle abnormalities of pulmonary function in association with the Pi-MZ genotype, including alterations in pressure/volume curves (157) .
Even among persons with normal baseline serum levels of API, genetic variation impairing the upregulation ofAPI during stress may confer increased susceptibility to COPD. In one study, a polymorphism in the 3' flanking region of the API gene has been reported to be present in 17% of patients with COPD but in only 5% of the general population of the United Kingdom (158) . Although it is not associated with abnormal API serum level or function, it has been suggested that this polymorphism lies within an enhancer sequence and may impair the acute phase increase in API expression (158, 159) .
Much less is known about the possible role of other protease inhibitor genes in the pathogenesis of COPD. The protease inhibitor aI-antichymotrypsin (ACT) is the major physiologic inhibitor of cathepsin G, an elastolytic protease produced by neutrophils, and has been observed to be protective against pancreatitis-induced lung injury in rats (160) . The gene encoding ACT is located on chromosome 14, in close proximity to the API gene (161) . Two mutations of the ACT gene were identified in a screening study of 200 COPD patients of German extraction and were associated in heterozygotes with a reduction in serum ACT activity to 62-75% of normal (162, 163) . These mutations were present in 1.5 and 4%, respectively, of patients with COPD but in none of 100 control subjects. This association of COPD and ACT mutations was not duplicated in other trials (164) . X2-Macroglobulin is a serum nonspecific antiprotease that appears in the sputum during infections (165) . Genetic variation in the ACT structure has been associated with premature lung disease (166, 167) , but these findings have not been consistently replicated and the role of a2-macroglobulin in lung disease remains unclear (168 (183, 184) in COPD patients, although the results have been inconsistent (173) .
A variety of other mediators of inflammation may play a role in the pathogenesis of COPD, though the understanding of their contributions remains in its infancy. The role of lymphocyte response, and mediators thereof, are under investigation. Lymphocytes appear to respond through TH-1 (185) mechanisms, and work on describing the mediators of this response has begun (186, 187) . Variation in certain mediators of inflammation, including tumor necrosis factor alpha and interleukin (IL)-8 (188), have also been found in COPD subpopulations, and IL-4 receptor blockade has been associated with a reduction in neutrophil survival (189) . A positive association between pulmonary surfactant and airways diameter has been described; surfactant proteins were observed to inhibit pulmonary inflammation (190) . Production of particular surfactant proteins is inhibited by tobacco smoking (191) . Linking of these observations in the pathogenesis of COPD has yet to be reported As genetic polymorphisms influencing expression or function of these and other components of the inflammatory cascade are discovered, their possible roles in the differential sensitivities to the development of COPD will be better understood.
An association between the presence of blood type A and COPD has been reported (192) (193) (194) , but others have failed to confirm this relationship (195, 196) . Many but not all people secrete the ABO blood group antigen into the upper and lower respiratory tract, and secretor status has inconsistently been associated with airflow limitation (168, 169, 197) .
Lewis blood group and Lewis antigen secretor status have also been reported to be associated with airflow limitation (198, 199) . In the absence of a consistent association with COPD, or a clear biologic rationale for such an association, the roles, if any, of blood antigen specificity and secretor status in the pathogenesis of COPD remain uncertain.
Genetic factors likely affect susceptibility to oxidative injury. Metabolic processes that are upregulated in response to proinflammatory stimulants (including electron transport in the mitochondria, enzymatic activity such as cyclooxygenase, and phagocytic activity in the white blood cells) generate part of the oxidative burden to the lung. Oxidants, as discussed above, may then damage the airways, resulting in chronic airflow obstruction. Lower levels of antioxidants have been correlated with airflow obstruction (200) . Urinary excretion of isoprostane2.III, a purported stable marker of oxidative stress, is increased in COPD patients (201) . Microsomal epoxide hydrolase (mEPHX), which detoxifies epoxides directly, has four described alleles. Weakened defenses to oxidative stress may occur through isomeric variation; Smith and Harrison (202) described a higher frequency of slow mEPHX enzyme among COPD patients that may expose the lungs to unscavenged free radicals. Oxidative balance has thus been implicated in the pathogenesis of COPD, but the role of the host in generating oxidative stress and balancing protective mechanisms needs further investigation.
Gene-Environment Interactions
Tobacco smoke exposure is the strongest environmental risk factor for COPD, but only about 15% of smokers develop the disease (52, 203) , and only 25-30% of smokers of 30 pack-years or more develop clinically apparent airflow obstruction (204, 205) . Even in the presence of small airways disease indicated by a reduced FEF25-75 (forced expiratory flow 25-75% of vital capacity), some smokers do not develop clinically significant airflow obstruction despite ongoing smoking for may years (206) . A recent family study compared the lung function of first-degree relatives of probands with early-onset COPD, none of whom had the Pi-ZZ genotype, to those of persons without a family history of COPD (207) . Among nonsmokers, lung function was similar between subjects with and without a relative with COPD. Among cigarette smokers, however, relatives of a person with COPD had a mean reduction of 13% in FEVi compared to subjects without a family history of smoking. These The best-characterized example of geneenvironment interaction in the pathogenesis of COPD is the interaction between severe API deficiency and tobacco smoking. As described above, severe API deficiency in persons with the Pi-ZZ genotype or other more rare genotypes, is associated with the premature development of severe emphysema. Among persons with severe API deficiency, those who smoke tobacco experience a more rapid rate of longitudinal lung function decline and more severe airflow obstruction than nonsmokers (146, 208) . A study from Sweden demonstrated that only 50% of Pi-ZZ smokers survived beyond 35 years of age, whereas Pi-ZZ nonsmokers had a 50% probability of surviving beyond age 57 (145) .
The example of genetically determined API deficiency predisposing to smokinginduced chronic airflow obstruction provides a paradigm of gene-environment interaction, consistent with current hypotheses concerning the pathogenesis of COPD. In this model, an inhaled environmental agent such as tobacco smoke induces an inflammatory response in the small airways that may result in irreversible damage to the small airways and centrilobular alveoli. This damage is mediated by proteolytic enzymes and oxygen free radicals, and the degree of damage depends on genetically controlled systems that modulate the inflammatory response and protect the lung from proteolytic and oxidant injury.
Another example of possible geneenvironment interaction is the hypothesized interaction between cigarette smoking and the intermediate degree of API deficiency found in heterozygotes with the Pi-MZ genotype. The putative role of the Pi-MZ genotype in the pathogenesis of COPD remains controversial; however, some reports suggest the possibility of an interaction between the Pi-MZ genotype and environmental exposures. Abnormalities of pulmonary function including abnormalities of airflow have been observed in heterozygotes who smoke (209, 210) Atopy, a genetically controlled trait, may lead to airway inflammation and asthma in genetically predisposed persons who are exposed to environmental aeroallergens. Asthma, in turn, appears to be a risk factor for the development of irreversible airflow obstruction that may ultimately be classified as COPD. Asthma, as well as airways hyperreactivity in the absence of asthma, has been associated with an accelerated rate of decline in FEV, (215) (216) (217) (218) , even after controlling for tobacco use. Although asthma and COPD are pathologically distinct (219) , chronic asthma may lead to some histopathologic changes resembling COPD, including inflammation with epithelial cell loss, squamous metaplasia, leukocyte infiltration, basement membrane thickening (220), as well as parenchymal destruction. The irreversible changes in airway histology seen in chronic asthma are often referred to as "airway remodeling" (221) . In addition, the radiographic (222) and physiologic (223, 224) changes of emphysema have been noted in nonsmoking chronic asthmatics. Chronic asthma can result in fixed airways obstruction with loss of elastic recoil and expiratory flow, and with increased total lung capacity. Although asthma is frequently associated with an increased diffusion capacity (224) (225) (226) (227) (228) (229) , a reduction in diffusing capacity has also been noted in patients with no radiographic evidence of emphysema but who have severe small airways disease (230) . Nonasthmatics with evidence of allergy to common aeroallergens have been reported to have a more rapid rate of longitudinal decline in pulmonary function (216, 218, 231) , although conflicting data have been reported (232) . In addition, one report suggests that exposure of sensitized persons to indoor allergens may result in accelerated longitudinal lung function decline even in the absence of asthma (218 
